Publications arising from this work

Rogowska AZ, Whitelaw DE, Lees WR, Gilliams AR, Ripley PM, Buonaccorsi GA, Hatfield AWR, Bown SG. (1999). Photodynamic therapy for palliation o f unresectable pancreatic cancer. Gut, 44, Abstract, W191.

Oral presentation at the British Society o f Gastroenterology, Aimual Meeting, Glasgow, 1999.

Rogowska AZ, Whitelaw DE, Lees WR, Gilliams AR, Ripley PM, Buonaccorsi GA, Hatfield AWR, Bown SG. (1999). Photodynamic therapy for palliation o f unresectable pancreatic cancer. Gastroenterology, 116, Abstract, G5026.

Rogowska AZ, Buonaccorsi GA, Mosse S, Connelly J, MacRobert AJ, Bown SG. (2000). Enhancement o f photodynamic therapy for pancreatic cancer using ALA with an iron chelator in hamsters. Gastroenterology, 118, Abstract 2787.

References

Ackroyd R, Brown N, Vernon D, Roberts D, Stephenson T. Marcus S, Stoddard C and Reed M. (1999). 5-aminolevulinic acid photosensitization o f dysplastic Barrett’s oesophagus; a pharmacokinetic study. Photochem Photobiol, 70, 656-662.

Ackroyd R, Davis M, Stephenson T, Brown N, Stoddard C, Reed M. (1998). PDT for barrett’s oesophagus: a randomised controlled trial. Abstract. RC172. 7^ Biennial Congress. International photodynamic association.

Abulafi AM, Allardice JT, Williams NS, Someren van N, Swain CP, Ainley CA. (1995). Photodynamic therapy for malignant tumours o f the ampulla o f Vater. Gut, 36, 853-856.

Agarwal ML, Clay ME, Harvey EJ, Evans HH, Antunez AR and Oleinick NL. (1991). Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res, 51, 5993-5996.

Ahlgren JD. (1996a). Epidemiology and risk factors in pancreatic cancer. Sem Oncol, 23,241-250.

Ahlgren JD. (1996b). Chemotherapy for pancreatic carcinoma. Cancer, 78, 654-663.

Allema JH, Reinders ME, van Gulik TM, Koelemay MJ, Van Leeuwen DJ, de Wit LT, Gouma DJ, Obertrop H. (1995). Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma o f the pancreatic head region. Cancer, 75, 2069-2076.

Almoguera C, Shibata D, Forrester K, Martin J, Amheim N, Perucho M. (1988).Most human carcinomas o f the exocrine pancreas contain mutant c-K-ras genes. Cell, 53, 549-554.

Andrejevic-Blant S, Hadjur Ch, Ballini J-P, Wagnieres G, Fontolliet Ch, Bergh van den H and Monnier P. (1997). Photodynamic therapy o f early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal drug-light interval. Br. J. Cancer, 76, 1021-1028.

Andrejevic-Blant S, Woodtli A, Wagnieres G, Fontolliet Ch, Bergh van den H and Monnier P. (1996). In vivo fluence rate effect in photodynamic therapy o f early cancers with tetra(m-hydroxyphenyl)chlorin. Photochem Photobiol, 64, 963-968.

Auerbach O, Garfinkel L. (1986). Histologic changes in pancreas in relation to smoking and coffee-drinking habits. Dig Dis Sci, 31, 1014-1020.

Bakkevold KE, Amesjo B, Kambestad B. (1992). Carcinoma o f the pancreas and papilla o f vater: presenting symptoms, signs, and diagnosis related to stage and tumour site. A prospective muticentre trial in 472 patients. Europ. J ?

Barkin JS, Goldberg RI, Sfakianakis GN, Levi J. (1986). Pancreatic carcinoma is associated with delayed gastric emptying. Dig Dis Sci, 31, 265-267.

Barkin JS, Goldstein JA. (1999). Diagnostic approach to pancreatic cancer. Gastroenterology Clin North. Am, 28, 709-722.

Barr H, Tralau CJ, Boulos PB, MacRobert AJ, Krasner N, Phillips D and Bown SG. (1990). Selective necrosis in dimethylhydrazine- induced rat colon tumours using phthalocyanine photodynamic therapy. Gastroenterology, 98, 1532-1537.

Barr H, Shepherd NA, Dix A, Roberts DJH, Tan WC, Krasner N. (1996). Eradication o f high-grade dysplasia in columnar-lined (Barrett’s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin DC. Lancet, 348, 584-585.

Barton CM, Staddon SL, Hughes CM, Hall PA, O ’Sullivan C, Klopper G, Russell RCG, Neoptolemos J, Williamson RCN, Lane DP, Lemoine NR. (1991). Abnormalities o f the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer, 64, 1076-1082.

Bech O, Philips D, Moan J, MacRobert AJ. (1997). A hydroxypyridinone (CP94) enhances protoporhyrin IX formation in 5-aminolaevulinic acid treated eells. J Photoehem Photobiol B: Biol, 41, 136-144.

Bedwell J, MacRobert AJ, Phillips D and Bown SG. (1992). Fluorescence distribution and photodynamie effect o f ALA-induced PPIX in the DMH rat eolonic tumour model. Br J Cancer, 65, 818-824.

Ben-Hur E, Green M, Prager A, Kol R and Rosenthal I. (1987). Phthaloeyanine photosensitization o f mammalian eells: bioehemieal and ultrastructural effeets. Photochem Photobiol. 46, 651-656.

Berg K, Anholt H, Bech O, Moan J. (1996). The influenee o f iron ehelators on the accumulation o f protoporhyrin IX in 5-aminolaevulenic acid-treated cells. Br. J. Cancer, 74, 688-697.

Berg K, Moan J. (1997). Lysosomes and microtubules as targets for photochemotherapy o f cancer. Photoehem Photobiol, 65, 403-409.

Berg K, Steen HB, Winkelman JW and Moan J. (1992). Synergestie effects o f photoactivated tetra(4-sulfonatophenyl)porphine and noeodazole on microtubule assembly, aceumulation o f cells in mitosis and eell survival. J Photoehem Photobiol, 13, 59-70.

Berger DH, Chang H, Wood M, Huang L, Heath CW, Lehman T, Ruggeri BA. (1999). Mutational activation o f K-ra^ in nonneoplastic exocrine pancreatie lesions in relation to cigarette smoking status. Caneer, 85, 326-332.

Bieligk S, Jaffe B. (1995). Islet eell tumours o f the panereas. Surg Clin North Am, 75, 1025-1040.

Birk D, Fortnagel G, Formentini A, Beger HG. (1998). Small earcinoma o f the panereas. Factors o f prognostic relevance. J Hepatobiliary Pancreat Surg, 5, 450-454.

B irt DF, Julius AD, White LT, Pour PM. (1989). Enhancement o f pancreatic carcinogenesisi in hamsters fed a high-fat diet ad libitum and at a controlled calorie intake. Cancer Res, 49, 5848-5851.

Bluemke DA, Cameron JL, Hruban RH, Pitt HA, Siegelman SS, Soyer P, Fishman EK. (1995). Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathological correlation. Radiology, 197, 381-385.

Bonnett R. (1995). Photosensitizers o f the porphyrin and phthalocyanine series for photodynamic therapy. Chem Soc Rev, 19-33.

Bonnett R. (1999). Photodynamic thrapy in historical perspective. Rev Contemp Pharmacotherapy, 10, 1-17.

Bonnett R, White RD, Winfield U-J and Berenbaum MC. (1989). Hydroporhyrins o f the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. Biochem J, 261,277-280.

Bottger TC, Storkel S, Wellek S, Stockle M, Junginger T. (1994). Factors influencing survival after resection o f pancreatic cancer. A DNA analysis and a histomorphologic study. Cancer, 73, 63-73.

Bown SG. (1990). Photodynamic therapy to scientists and clinicians- one world or two ? J Photochem Photobiol, B, Biol, 6 1-12.

Boyle RW, Dolphin D. (1996). Structure and biodistribution relationships o f photodynamic sensitizers. Photochem Photobiol, 64, 469-485.

Boyle P, Maisonneuve P, Bueno de M esquita B, Ghadirian P, Howe GR, Zatonski W, Baghurst P, Moerman CJ, Simard A, M iller AB, Przewoniak K, McMichel AJ, Hsieh CC, W alker AM. (1996). Cigarette smoking and pancreatic cancer: a case- control study o f the SEARCH programme o f the I ARC. Int J Cancer, 67, 63-71.

Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. (1995). Treatment and survival in 13560 patients with pancreatic cancer, and incidence o f the disease, in the West Midlands: an epidemiological study. Br J Surg., 82,111-115.

Authors’ reply. (1996) Br J Surg., 83, 874.

Brasseur N, Lewis K, Rousseau J and Lier van JE. (1996). Measurement o f tumour vascular damage in mice with ^^""Tc-MIBI following photodynamic therapy. Photochem Photobiol, 64, 702-706.

Briachotte D, Savary J-F, Glanzmann T, Monnier P, Wagnieres G and bergh van den H. (1996). Optimizing light dosimetry in photodynamic therapy o f the bronchi by fluorescence microscopy. Lasers Med Sci, 11, 247-254.

Briviba K, Klotz 1-0, Sies H. (1997). Toxic and signalling effects o f photochemically or chemically generated singlet oxygen in biological systems. Biol Chem, 378, 1259-

1265.

Brittenham GM. (1992). Development o f iron-chelating agents for clinical use. Blood, 80, 569-574.

Bueno de M esquita HB, Maisonneuve P, Moerman CJ, Runia S, Boyle P. (1992). Lifetime consumption o f alcoholic beverages, tea and coffee and exocrine carcinoma o f the pancreas: a population-based case-control study in the Netherlands. Int. J. Cancer, 50, 514-522.

Bueno de Mesquita HB, Maisonneuve P, Moerman CJ, Walker AM. (1992). Aspects o f medical history and exocrine carcinoma o f the pancreas: a population -based case- control study in the Netherlands. Int J Cancer, 52, 17-23.

Burris HA, Moore MJ, Andersen J, Green M R et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 15, 2403-2413.

Cable H, Lloyd JB. (1999). Cellular uptake and release o f two contrasting iron chelators. J Pharm Pharmacol, 51, 131-134.

Caldas C, Hahn S, Hruban RH, Redston MS, Yeo CJ, Kern SE. (1994). Detection o f ¥^-ras mutations in the stool o f patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res, 54, 3568-3573.

Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. (1993). One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg, 217, 430-438.

Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G, Blatter J. (1996). Phase II study o f gemcitabine in patients with advanced pancreatic cancer. Br J Cancer, 73, 101-105.

Carriaga MT, Henson DE. (1995). Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer, 75, 171-190.

Casas A, del C Battle AM, Butler AR, Robertson D, Brown EH, MacRobert A, Riley PA. (1999). Comparative effect o f ALA derivatives on protoporphyrin DC production in human and rat skin organ cultures. Br J Cancer, 80, 1525-1532.

Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG. (1994). Phase II trial o f gemcitabine (2,2’- difluorodeoxycytidine) in patients with adenocarcinoma o f the pancreas. Invest N Drugs, 12, 29-34.

Chatlani PT, Nuutinen PJO, Toda N, Barr H, M acRobert AJ, Bedwell J, Bown SG. (1992). Selective necrosis in hamster pancreatic tumours using photodynamic therapy with phthalocyanine photosensitization. Br J Surg, 79, 786-790.

Chang SC, MacRobert AJ and Bown SG. (1996). Biodistribution o f protoporhyrin DC in rat urinary bladder after intravesical intillation o f 5-aminolevulinic acid. J Urol., 155, 1744-1748.

Chang SC, MacRobert AJ, Porter JB, Bown SG. (1997). The efficacy o f an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5- aminolaevulinic acid administration: an in vivo study. J Photochem Photobiol B: Biol, 38, 114-122.

Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. (1997). The clinical utility o f endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging o f pancreatic carcinoma. Gastrointest Endosc, 45, 387-393.

Chen Q, Wilson BC, Shetty SD, Patterson MS, Cemy JC and Hetzel FW. (1997). Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. Radiat Res, 147, 86-91.

Clavel F, Benhamou E, Auquier A, Tarayre M, Flamant R. (1989). Coffee, alcohol, smoking and cancer o f the pancreas: a case-control study. Int J Cancer, 43, 17-21.

Compton CC , Mulvihill SJ. (1997). Prognostic factors in pancreatic carcinoma. Surg. Oncol Clin North Am, 63, 533-554.

Conlon KC, Klimstra DS, Brennan MF. (1996). Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis o f 5-year survivors. Ann Surg, 223, 273-279.

Connolly MM, Dawson PJ, Michelassi F, Moossa AR, Lowenstein F. (1987). Survival in 1001 patients with carcinoma o f the pancreas. Ann Surg, 206, 366-370.

Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R and Porter JB. (1996). The relationship o f intracellular iron chelation to the inhibition and regeneration o f human ribonucleotide reductase. J Biol Chem, 271, 20291-20299.

Crinnon JN, Williamson RCN. (1997). Pancreatic neoplasia. Hepatobiliary and pancreatic surgery. Edited by J Garden. Saunders Company.

Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK, Barlow JF. (1990). A phase III trial on the therapy o f advanced pancreatic carcinoma. Evaluations o f the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer, 65, 2207-2212.

Cumow A, Mcllroy BW, Postle-Hacon MJ, Porter JB, MacRobert AJ & Bown SG. (1998). Enhancement o f 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridione iron-chelating agents. Br J Cancer, 78,

1278-1282.

Cumow A, Mcllroy BW, Postle-Hacon MJ, MacRobert AJ & Bown SG. (1999). Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem Photobiol, 69, 71-76.

Cumow A. Thesis. 1999.

Cuzik J, Babiker AG. (1989). Pancreatic cancer, alcohol, diabetes mellitus and gall­ bladder disease. Int J Cancer, 43, 415-421.

Daniell MD, Hill JS. (1991). A history o f photodynamic therapy. Aust N Z J Surg, 61,340-348.

Davids PH, Groen AK, Rauws EAJ, Tytgat GNJ, Huibregtse K. (1992). Randomised trial o f self-expanding metal stents for distal malignant biliary obstmction. Lancet, 340, 1488-1492.

Deahl JT, Oleinick NL and Evans H. (1993). Large mutagenic lesions are induced by photodynamic therapy in murine L5178Y lymphoblasts. Photochem Photobiol, 58, 259-264.

Diamond I, Granelli S, MCDonagh AF, Nielsen S, Wilson CB, Jaenicke R. (1972). Photodynamic therapy o f malignant tumours. Lancet, ii, 1175-1177.

Diehl SJ, Lehmann KJ, Sadick M, Lachmann R, Georgi M. (1998). Pancreatic cancer: value o f dual-phase helical CT in assessing resectability. Radiology, 206, 373-378.

DiMagno EP, Reber HA, Tempero MA. (1999). AGA technical review on the epidemiology, diagnosis and treatment o f pancreatic ductal adenocarcinoma. Gastroenterology, 117, 1464-1485.

Ding X, Flatt PR, Permert J, Adrian TE. (1998). Pancreatic cancer cells selectively stimulate islet |3 cells to secrete amylin. Gastroenterology, 114, 130-138.

Dowdle E, Mustard P, Spong N. (1968). The metabolism o f (5-15C) aminolaevulinic acid in normal and porhyric human subjects. Clin Sci, 34, 233-240.

Dougherty TJ, Gomer CJ, Henderson BW, Jori GJ, Kessel D, Korbelik M, Moan J, Peng Q. (1998). Photodynamic therapy. J Natl Cancer Inst, 90, 889-905.

Dougherty TJ, Grindey GB, Fiel R, Weishaupt KR, Boyle DG. (1975). Photoradiation therapy. II. Cure o f animal tumours with hematoporphyrin and light. J Natl Cancer Inst, 55, 115-119.

Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. (1978). Photoradiation therapy for the treatment o f malignant tumours. Cancer Res, 38, 2628-2635.

Egami H, Takiyama Y, Cano M, Houser WH, Pour PM. (1989). Establishment o f hamster pancreatic ductal carcinoma cell line (PC-1) producing blood group-related antigens. Carcinogenesis, 10, 861-869.

Ell C, Gossner L, May A, Shneider HT, Hahn EG, Solte M et al. (1998). Photodynamic ablation o f early cancers o f the stomach by means o f MTHPC and laser irradiation: preliminary clinical experience. Gut, 43, 345-349.

Epemolu RO, Ackerman R, Porter JB, Hider RC, Damani LA and Singh S. (1994). HPLC determination o f l,2-diethyl-3-hydroxypiridin-4-one (CP94), its iron complex [Fe(III) (CP9 4 3] and glucuronide conjugate [CP94-GLUC] in serum and urine o f thalassaemic patients. J Pharm Biomed Anal, 12, 923-930.

Evans HH, Homg M-F, Ricanati M, Deahl JT and Oleinick NL. (1997). Mutagenicity o f photodynamic therapy as compared to UVC and ionising radiation in human and murine lymphoblast cell lines. Photochem Photobiol, 56, 690-696.

Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Chamsangavej C, Fenoglio CJ, Ames FC. (1992). Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma o f the pancreas. Arch Surg, 127,

1335-1339.

Evenson F, Moan J. (1982). Photodynamic action and chromosal damage: A comparison o f haematoporphyrin derivative (HpD) and light with X-irradiation. Br J Cancer, 45, 456-465.

Everard S, Keller P, Hajri A, Baboni G, Mendoza-Burgos L, Damge C, Marescaux J, Aprahamian M. (1994). Experimental pancreatic cancer in the rat treated by photodynamic therapy. Br J Surg, 81, 1185-1189.

Faivre J, Forman D, Esteve J, Obradovic M, Sant M and the EUROCARE working group. (1998). Survival o f patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. Eur J Cancer, 34, 2184-2190.

Falk RT, Pickle LW, Fontham ET, Correa P, Fraumeni JF. (1988). Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidemiol,

128, 324-336.

Ferraudi G, Arguello GA, All H, Lier van JE. (1988). Types I and II sensitised photooxidation o f aminoacid by phthalocyanines: a flash photochemical study. Photochem Photobiol, 47, 657-660.

Fem icci JT, Wittenberg J, Margolies MN, Carey RW. (1979). Malignant seeding o f the tract after thin-needle aspiration biopsy. Radiology, 130, 345-346.

Fingar VH, Wieman TJ and Doak KW. (1990). Role o f tromboxane and prostacyclin release on photodynamic therapy induced tumour destruction. Cancer Res, 50, 2559- 2603.

Fingar VH, Wieman TJ, Wiehle SA and Cerrito PB. (1992). The role o f micro vascular damage in photodynamic therapy: the effect o f treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res, 52, 4914-4921.

Fortner JG, Klimstra DS, Senie RT, Maclean BJ. (1996). Tumour size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg, 223,

147-153.

Foster TH, Murant RS, Bryant RG, Knox RS, Gibson SL, H ilf R. (1991). Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res, 126, 296- 303.

Freeny PC. (1999). Pancreatic imaging. New modalities. Gastroenterolgy Clin North Am,28, 723-746.

Freeny PC, Marks WM, Ryan JA, Traverse LW. (1988). Pancreatic ductal adenocarcinoma: diagnosis and staging with dynamic CT. Radiology, 166, 125-133.

Fuchs CS, Colditz GA, Stampfer MJ, Giovanucci EL, Hunter HJ, Rimm EB, W illett WC, Speizer FE. (1996). Prospective study o f cigarette smoking and the risk o f pancreatic cancer. Arch Intern Med, 156, 2255-2260.

Furuya N, Kawa S, Akamatsu T, Furihata K. (1997). Long-term follow-up o f patients with chronic pancreatitis and ¥^-ras gene mutation detected in pancreatic juice. G astroenterology, 113, 593-598.

Gansauge S, Schmid RM, Muller J, Adler G, Mattfeld T, Beger HG. (1998). Genetic alterations in chronic pancreatitis : evidence for early occurrence o f p53 but not K- ras mutations. Br J Surg, 85, 337-340.

Gastrointestinal Tumor Study Group. (1985). Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment o f locally unresectable pancreatic carcinoma. Cancer, 56, 2563-2568.

Gastrointestinal Tumor Study Group. (1987). Further evidence o f effective adjuvant combined radiation and chemotherapy following curative resection o f pancreatic cancer. Cancer, 59, 2006-2010.

Gastrointestinal Tumor Study Group. (1988). Treatment o f locally unresectable carcinoma o f the pancreas: comparison o f combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst, 80, 751-755.

Gates LK, Urlich CD, Whitcomb DC. (1999). Hereditary pancreatitis. Gene defects and their implications. Surg Clin North Am., 79, 711-722.

Geel van IPJ, Oppelaar H, Marijnissen JPA and Stewart FA. (1996). Influence o f fractionation and fluence rate in photodynamic therapy with Photoffin or mTHPC. Radiat Res, 145, 602-609.

Geel van IPJ, Oppelaar H, Oussoren YG, Valk van der MA and Stewart FA. (1995). Photosensitising efficacy o f MTHPC-PDT compared to Photofiin-PDT in the RIFl mouse tumour and normal skin. Int J Cancer, 60, 388-394.

Geer RJ, Brennan MF. (1993). Prognostic indicators for survival after resection o f pancreatic adenocarcinoma. Am J Surg, 165, 68-73.

Gessner CE, Baillie J. (1996). P53 levels in the evaluation o f malignant/benign pancreatobiliary disease: hope or hype?. Am J Gastroenterology, 94, 401-402.

Ghadirian P, Simard A, Baillargeon J. (1991). Tobacco, alcohol, and coffee and cancer o f the pancreas. A population-based, case-control study in Quebec, Canada. Cancer, 67, 2664-2670.

Gibson SL, H ilf R. (1985). Interdependence o f fluence, drug dose and oxygen on hematoporphyrin derivative induced photosensitization o f tumour mitochondria. Photochem Photobiol, 42, 367-373.

Glanzmann T, Hadjur C, Zellweger M, Grosjean P, Forrer M, Ballini J-P, Monnier P, Bergh van den H, Lim CK and Wagnieres G. (1998). Pharmcokinetics o f tetra(m- hydroxyphenyl)chlorin in human plasma and individualized light dosimetry in photodynamic therapy. Photochem Photobiol, 67, 596-602.

Gloor B, Todd KE, Reber HA. (1997). Diagnostic workup o f patients with suspected pancreatic carcinoma. Cancer, 79, 1780-1786.

Gold EB. (1995). Epidemiology o f and risk factors for pancreatic cancer. Surg Clin North Am, 75, 819-843.

Gold EB, Cameron JL. (1993). Chronic pancreatitis and pancreatic cancer (editorials). N Engl J Med, 328, 1485-1486.

Gomer CJ, Rucker N, Banerjee A and Benedict WF. (1983). Comparison o f mutagenicity and induction o f sister chromatid exchange in Chinese hamster cells exposed to hematoporphyrin derivative photoradiation, ionozing radiation, or ultraviolet radiation. Cancer Res, 43, 2622-2627.

Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG and Ell C. (1998). Photodynamic ablation o f high-grade dysplasia and early cancer in Barrett’s